Empaveli
Empaveli ingredients
| Active ingredient | Strength |
|---|---|
| Pegcetacoplan | 1080 mg/20mL |
What Empaveli is used for
The FDA lists the approved uses on the official label (below). In the EU, pegcetacoplan is approved as Aspaveli for:
Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. Aspaveli is indicated for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Empaveli
- Generic name
- Pegcetacoplan
- Made by
- Apellis Pharmaceuticals, Inc.
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- Complement Inhibitor
- FDA approval
- New drug application (NDA) NDA215014
- On the US market since
- 2021
Official information
- Empaveli prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Pegcetacoplan)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Empaveli?
Empaveli (Pegcetacoplan) is a specialist medicine made by Apellis Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Empaveli?
Empaveli contains Pegcetacoplan (1080 mg/20mL).
Is Empaveli approved in Europe?
The same active substance is approved in the EU as Aspaveli.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA